Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will support Avextra’s continued expansion of its European distribution channels and accelerate clinical trials to create new evidence-based treatment options for specific indications.

Read more